Schaefer N, Moj D, Lehr T, Schmidt P, Ramsthaler F
Int J Legal Med. 2017; 132(2):415-424.
PMID: 29196879
DOI: 10.1007/s00414-017-1754-8.
Kumar V, Garg R, Gupta N, Bharati S
BMJ Case Rep. 2016; 2016.
PMID: 27986693
PMC: 5174766.
DOI: 10.1136/bcr-2016-217174.
Thakkar N, Salerno S, Hornik C, Gonzalez D
Pharm Res. 2016; 34(1):7-24.
PMID: 27585904
PMC: 5177463.
DOI: 10.1007/s11095-016-2033-y.
Bosilkovska M, Walder B, Besson M, Daali Y, Desmeules J
Drugs. 2012; 72(12):1645-69.
PMID: 22867045
DOI: 10.2165/11635500-000000000-00000.
Bachmann K, Belloto Jr R
Drugs Aging. 1999; 15(3):235-50.
PMID: 10503815
DOI: 10.2165/00002512-199915030-00006.
Pharmacokinetics of opioids in liver disease.
Tegeder I, Lotsch J, Geisslinger G
Clin Pharmacokinet. 1999; 37(1):17-40.
PMID: 10451781
DOI: 10.2165/00003088-199937010-00002.
Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.
Somogyi A, Nation R, OLWENY C, Tsirgiotis P, van Crugten J, Milne R
Clin Pharmacokinet. 1993; 24(5):413-20.
PMID: 8504624
DOI: 10.2165/00003088-199324050-00005.
Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses.
Barbhaiya R, Shukla U, Pfeffer M, PITTMAN K, Shrotriya R, Laroudie C
Eur J Clin Pharmacol. 1994; 46(1):41-7.
PMID: 7911763
DOI: 10.1007/BF00195914.
Alteration of drug-protein binding in renal disease.
Reidenberg M, Drayer D
Clin Pharmacokinet. 1984; 9 Suppl 1:18-26.
PMID: 6705423
DOI: 10.2165/00003088-198400091-00003.
Anticonvulsant drugs. An update.
Eadie M
Drugs. 1984; 27(4):328-63.
PMID: 6327221
DOI: 10.2165/00003495-198427040-00003.
Disease-induced changes in the plasma binding of basic drugs.
Piafsky K
Clin Pharmacokinet. 1980; 5(3):246-62.
PMID: 6156048
DOI: 10.2165/00003088-198005030-00004.
Protein binding and CSF penetration of phenytoin following acute oral dosing in man.
Brodie M, Muir S, Agnew E, Macphee G, Volo G, Teasdale E
Br J Clin Pharmacol. 1985; 19(2):161-8.
PMID: 3986076
PMC: 1463704.
DOI: 10.1111/j.1365-2125.1985.tb02627.x.
Dihydrocodeine in renal failure.
Brown A
Br Med J (Clin Res Ed). 1985; 290(6477):1287.
PMID: 3921188
PMC: 1415865.
DOI: 10.1136/bmj.290.6477.1287.
Dihydrocodeine in renal failure: further evidence for an important role of the kidney in the handling of opioid drugs.
Barnes J, Williams A, Tomson M, Toseland P, Goodwin F
Br Med J (Clin Res Ed). 1985; 290(6470):740-2.
PMID: 3918735
PMC: 1418472.
DOI: 10.1136/bmj.290.6470.740.
Enhanced oral bioavailability of meptazinol in cirrhosis.
Birnie G, Thompson G, Murray T, Watkinson G, Brodie M
Gut. 1987; 28(3):248-54.
PMID: 3570028
PMC: 1432689.
DOI: 10.1136/gut.28.3.248.
Pharmacokinetics of sufentanil in patients undergoing renal transplantation.
Fyman P, Reynolds J, Moser F, Avitable M, Casthely P, Butt K
Can J Anaesth. 1988; 35(3 ( Pt 1)):312-5.
PMID: 2968186
DOI: 10.1007/BF03010638.
Clinical pharmacokinetics in organ transplant patients.
Venkataramanan R, Habucky K, Burckart G, Ptachcinski R
Clin Pharmacokinet. 1989; 16(3):134-61.
PMID: 2656047
DOI: 10.2165/00003088-198916030-00002.
Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part II).
Zini R, Riant P, Barre J, Tillement J
Clin Pharmacokinet. 1990; 19(3):218-29.
PMID: 2203581
DOI: 10.2165/00003088-199019030-00005.
The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients.
Milne R, Nation R, Somogyi A, Bochner F, Griggs W
Br J Clin Pharmacol. 1992; 34(1):53-9.
PMID: 1633068
PMC: 1381375.
DOI: 10.1111/j.1365-2125.1992.tb04107.x.
Two-fold interindividual variation in plasma protein binding of phenytoin in patients with epilepsy.
Barth N, Alvan G, Borga O, Sjoqvist F
Clin Pharmacokinet. 1976; 1(6):444-52.
PMID: 1024769
DOI: 10.2165/00003088-197601060-00004.